Beam Therapeutics

What They Do

Developer of genome editing technologies.

Founded in

2017

Total Funding

$87M

Notable Investors

ARCH Venture Partners


What investment size are you considering?*

$


*Please note: this is not a commitment to nor guarantee of availability and pricing for this investment. The more information you can provide us about your interest, the easier it will be to reserve your allocation.

About Beam Therapeutics

Over half of the genetic errors associated with disease result from a single-letter change in the billions of bases that form the genome. In other cases, certain natural genetic variations in DNA are known to protect against disease. By changing a single letter – to eliminate errors or write in protective changes – in enough cells, base editing may help us prevent, modify, and even cure a wide range of diseases affecting patients’ lives.

https://beamtx.com/

Recent Press

Funding History

  • April 2018 $13,000,000
  • May 2018 $74,000,000

Investor Track Record

Management

  • J. Keith Joung, Co-Founder
  • Giuseppe Ciaramella, Chief Scientific Officer
  • David R. Liu, Co-Founder
  • Feng Zhang, Co-Founder and Board Member
  • John Evans, Chief Executive Officer and Board Member

Some data provided by Crunchbase

Have questions?